Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
about
Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescentsPopulation pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.Tips and traps analyzing pediatric PK data.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyProspective validation of neonatal vancomycin dosing regimens is urgently needed.Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline.Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.Association between vancomycin trough concentration and area under the concentration-time curve in neonatesPharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents.The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.Optimization of vancomycin dosing in very low-birth-weight preterm neonates.A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.Clinical pharmacokinetics of vancomycin in the neonate: a reviewPopulation pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease.Pharmacokinetic studies in infants using minimal-risk study designsUse of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens.Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtrationTowards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.Designing a Pediatric Study for an Antimalarial Drug by Using Information from AdultsExternal Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.Developmental pharmacology: neonates are not just small adults...Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in NeonatesMorphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial.Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trialScaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.Vancomycin: a review of population pharmacokinetic analyses.Neonatal pharmacology: extensive interindividual variability despite limited size.Population pharmacokinetic analysis during the first 2 years of life: an overview.The interplay between drugs and the kidney in premature neonates.Developmental pharmacokinetics in neonates.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future.
P2860
Q30832465-3F7BB9BD-3A93-4E5A-8B91-DB6BA73DE20EQ33797950-28C29A0E-F8B7-413A-966F-9940B6DAE6C7Q33820152-8B5C1B6E-32B4-4A9B-B3FA-3B1AD58BD50DQ33827819-BD08C8D1-477D-409A-A68A-608042FF4675Q33906451-B447AD73-579D-41DA-AC4F-3342889AA04CQ34381352-B6CE74AC-1D9E-4E34-95CF-159E17D23B9EQ34570930-A2F15BBA-EDD8-4945-B00C-B165753152CAQ34596435-470A98F1-6609-42E4-8E62-542B8BD825CEQ34737758-11889FC7-CD66-4F6B-BEFD-AFBB9D1D357DQ35065937-A9E88413-0019-48CC-A834-426B4051285FQ35238140-22743A9B-FD67-414B-B077-D940BAEE1D13Q35564749-364C4ED1-2840-4011-A852-6452BD49BF24Q35949142-030E2A7F-5FD8-49AB-8F08-D6CF1FB60CC0Q36086339-9983FEF5-AEA7-4964-8C7A-175652AC7205Q36104107-3AC6B787-A62C-4F67-9D2D-65B8100CB383Q36172421-9076096C-AE0B-4F02-9380-E24BF031F17EQ36216479-48D6B245-00DC-44D9-A896-97AC53FE5195Q36239801-B72F28CE-2117-49F9-9833-52A9AEE902CDQ36438116-A9410BD6-AB0A-408A-9CA4-574BC43910CBQ36473125-0592D04B-0A06-42B4-8CB3-A2DA738001CEQ36568925-FB84FDBE-3942-491F-AE08-C6256B88ED9BQ36571794-692C77AE-527A-4F49-96EA-F124BECEBD42Q36644652-78BF9F26-BDE3-483A-9FA1-CED18D367B2CQ36729959-7A7A5536-D130-49EE-81E4-CA82D8A25C8EQ37127683-D7C6D4E1-966C-410A-8479-EF3883E80DBCQ37231685-B62B1A0A-C5A1-463C-B1A7-BF6A7150891BQ37322083-4AC480AA-FFC0-48F6-A511-DD172CFF2F8DQ37429615-4E31E077-0F7E-44EC-8112-A6BA6EE26257Q37544540-388766A9-EC1E-4C9E-9F59-00F5BC1F40A6Q37690306-40B7469E-3159-470D-96DB-34C081E526C2Q37695055-1B9F8C2F-5956-4851-A771-B0DCFEE7F6A2Q37712974-B2943322-CA1D-4514-B76A-EBB707C63411Q37965578-86EEB130-CD2D-4563-96E2-16B6C9047B4AQ38000252-4DDCD4DA-B41C-4289-9FED-CC06E230CC45Q38062388-8CB3C767-9BFE-4ECB-A910-BEB34CFA0F34Q38161817-0051295A-AEE1-4EB4-AE06-C98E795C6C02Q38178316-49C0C10B-CD3A-4EC7-98CE-26BF143587F6Q38215682-AF57685B-3370-4218-AAF0-25603573A0B5Q38258649-549E971E-7723-47BC-A150-312772356D37Q38563371-098DF557-832A-4BC4-90E6-2B5F3FCD6822
P2860
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
@ast
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
@en
type
label
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
@ast
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
@en
prefLabel
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
@ast
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
@en
P2093
P2860
P1476
Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance
@en
P2093
Brian J Anderson
John N Van den Anker
Nicholas H G Holford
Veerle Cossey
P2860
P356
10.1111/J.1365-2125.2006.02725.X
P407
P577
2006-07-21T00:00:00Z